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A B S T R A C T
Background
Combination therapies are frequently recommended as maintenance therapy for people with asthma, whose disease is not adequately
controlled with inhaled steroids. Fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F) have been assessed against
their respective monocomponents, but there is a need to compare these two therapies on a head-to-head basis.
Objectives
To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function.
Search strategy
We searched the Cochrane Airways Group register of trials with prespecified terms. We performed additional hand searching of
manufacturers’ web sites and online trial registries. Searches are current to May 2009.
Selection criteria
Randomised studies comparing fixed dose FP/SAL and BUD/F were eligible, for a minimum of 12 weeks. Crossover studies were
excluded. Our primary outcomes were: i) exacerbations requiring oral steroid bursts, ii) hospital admission and iii) serious adverse
events.
Data collection and analysis
Two authors independently assessed studies for inclusion in the review. We combined continuous data outcomes with a mean difference
(MD), and dichotomous data outcomes with an odds ratio (OR).
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Main results
Five studies met the review entry criteria (5537 adults). Primary outcomes: The odds of an exacerbation requiring oral steroids did not
differ significantly between treatments (OR 0.89; 95% CI 0.74 to 1.07, four studies, 4949 adults). The odds of an exacerbation leading
hospital admission were also not significantly different (OR 1.29; 95% CI 0.68 to 2.47, four studies, 4879 participants). The odds of
serious adverse events did not differ significantly between treatments (OR 1.47; 95% CI 0.75, 2.86, three studies, 4054 participants).
Secondary outcomes: Lung function outcomes, symptoms, rescue medication, exacerbations leading ED visit/hospital admission and
adverse events did not differ statistically between treatments.
Authors’ conclusions
The evidence in this review indicates that differences in the requirement for oral steroids and hospital admission between BUD/F and
FP/SAL do not reach statistical significance. However, the confidence intervals do not exclude clinically important differences between
treatments in reducing exacerbations or causing adverse events. The width of the confidence intervals for the primary outcomes justify
further trials in order to better determine the relative effects of these drug combinations. Although this review sought to assess the
effects of these drugs in both adults and children, no trials were identified in the under-12s and research in this area is of a high priority.
P L A I N L A N G U A G E S U M M A R Y
The effects of different combinations of inhaled steroids and long-acting beta-agonists for chronic asthma
Persistent asthma often requires the combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA). This sys-
tematic review examined randomised controlled trials comparing two commonly available combinations administered at fixed dose
with a single inhaler, fluticasone/salmeterol (FP/SAL) and budesonide/formoterol (BUD/F). We found that the number of adults who
required treatment with oral steroids or admission to hospital was similar between the treatments, but that additional trials would
improve the precision of our estimates. No statistical differences were found for pulmonary function, rescue medication use and adverse
events. Well-designed studies on these questions on different types of patients are needed to confirm and to better explain these findings.
In particular studies which assess the effects of these therapies in children are of a high priority.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Combination fluticasone/salmeterol or budesonide/formoterol for chronic asthma in adults
Patient or population: patients with chronic asthma in adults1
Settings: community
Intervention: combination fluticasone/salmeterol or budesonide/formoterol
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Combination budes-
onide/formoterol in one
inhaler device
Combination fluticas-
one/salmeterol in one in-
haler device
Participants experienc-
ing exacerbations re-
quiring oral steroid
treatment
Follow-up: mean 6
months
106 per 10002 95 per 1000
(81 to 113)
OR 0.89
(0.74 to 1.07)
4949
(4 studies)
⊕⊕⊕©
moderate3
Participants experienc-
ing exacerbations re-
quiring admission to
hospital
Follow-up: mean 6
months
7 per 10002 9 per 1000
(5 to 17)
OR 1.29
(0.68 to 2.47)
4879
(4 studies)
⊕⊕⊕©
moderate3
Asthma-related serious
adverse event
Follow-up: mean 6
months
7 per 10002 10 per 1000
(5 to 20)
OR 1.47
(0.75 to 2.86)
4054
(3 studies)
⊕⊕⊕©
moderate3
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. No studies have been found in children. The findings of this review are only applicable to adults.
2. The mean event rate in the BDF arms of the trials was used to calculate the assumed risk.
3. The confidence interval is wide and could change with the addition of new evidence.
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B A C K G R O U N D
Asthma is a chronic inflammatory disease of the airways, and anti-
inflammatory treatment is a cornerstone of asthma therapy. Treat-
ment with inhaled corticosteroids (ICS) improves lung function
and reduces asthma symptoms in mild persistent asthmatic pa-
tients (Adams 2008). Many patients remain symptomatic despite
using optimal doses of ICS. However, patients do benefit by the
addition of an inhaled long-acting beta2-agonist (LABA). This
approach further improves lung function and quality of life in
patients with moderate to severe persistent asthma (Ni Chroinin
2005).
The principal advantage of combining ICS and LABA in one in-
haler is the simultaneous delivery of two effective inhaled ther-
apies. This may lead users to better adhere to dosing regimens,
especially given concerns over the use of LABA therapy without a
regular background steroid (Walters 2007). Clinicians and people
with asthma are faced with a choice between two treatments as
maintenance treatment of asthma: the ICS fluticasone and LABA
salmeterol preparation marketed as ’Seretide’, ’Advair’ or ’Viani’,
and the ICS budesonide and LABA formoterol preparation mar-
keted as ’Symbicort’.
There is some uncertainty as to which particular combination may
be suitable. Previous assessments have considered the addition of
anyLABA to any ICSwhen the dose of ICS is increased orwhen the
study drugs are titrated according to symptoms (Greenstone 2005;
Gibson 2005). Although the LABAs commonly used in combi-
nation preparations have a similar duration of effect of around 12
hours or more, salmeterol and formoterol also have differing phar-
macological properties. The onset of action of formoterol is faster
than that of salmeterol (Palmqvist 1997; vanNoord 1996) and has
as rapid an onset of action as salbutamol in asthma (Cazzola 2002).
Some differences exist also between fluticasone and budesonide
despite the shared anti-inflammatory effect (Adams 2007), and so
a systematic exploration of the relative efficacy of these different
drug combinations is justified.
O B J E C T I V E S
Tocompare the combinations of salmeterol/fluticasone andbudes-
onide/formoterol in single inhaler devices in chronic asthma in
terms of asthma control, safety and lung function.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, clinical trials comparing single inhaler devices con-
taining combination fluticasone and salmeterol versus budesonide
and formoterol. Only studies with a parallel design were eligible
as the minimum washout period of inhaled steroids has not been
adequately established.
Types of participants
Adults and children with a diagnosis of chronic asthma. We ac-
cepted trialist-defined asthma. Any severity of asthma and patients
on any co-intervention were eligible (as long as the co-interven-
tions were not part of the randomised treatment) but studies on
acute asthma carried out in emergency departmentswere excluded.
Types of interventions
The preparations considered by this review were the combina-
tion of the inhaled steroid fluticasone and long-acting beta-ago-
nist salmeterol (FP/SAL) against the inhaled steroid budesonide
and long-acting beta-agonist formoterol (BUD/F) in one inhaler
device. We included studies which assessed the combination of
drugs in either metered dose inhalers (MDI) or dry powder in-
haler (DPI). We considered fixed dose comparisons between these
preparations and we have excluded studies assessing the efficacy
and safety of different dosing strategies of budesonide/formoterol
(’single inhaler therapy’ or ’adjustable maintenance dosing’) with
fixed dose fluticasone/salmeterol. Studies had a minimum dura-
tion of 12 weeks in order to meet the entry criteria of this review.
Types of outcome measures
Primary outcomes
1. Exacerbations of asthma requiring oral steroids
2. Exacerbations of asthma requiring hospital admission
3. Serious adverse events (including asthma-related death and
intubation)
Secondary outcomes
1. Exacerbations leading to ED visit/admission to hospital
2. Diary card morning and evening peak expiratory flow (PEF)
3. Clinic spirometry (FEV1, clinic PEF, FVC)
4. Rescue medication use
5. Symptoms
6. Quality of life
7. Adverse events
8. Study withdrawal
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Search methods for identification of studies
Trials were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and hand searching of res-
piratory journals and meeting abstracts. All records in the Spe-
cialised Register coded as ’asthma’ were searched using the follow-
ing terms:
(“single inhaler” or symbicort or seretide or advair or viani) or
((steroid* or corticosteroid* or ICS or fluticasone or FPor Flixotide
or budesonide or BUD or Pulmicort) and (“long acting beta ag-
onist*” or “*beta-agonist*” or LABA* or salmeterol or serevent or
formoterol or eformoterol or oxis or foradil))
Reference lists of all primary studies and review articles were re-
viewed for additional references. Authors of identified randomised
trials were asked about knowledge of other published and unpub-
lished studies. Manufacturers of combination single inhaler de-
vices were contacted regarding other published and unpublished
studies.
We contacted trialists and manufacturers in order to ob-
tain unreported data and to establish whether other un-
published or ongoing studies are available for assessment.
We undertook additional hand searching of clinical trial
web sites (www.clinicalstudyresults.org; www.clinicaltrials.gov;
www.fda.gov) and the clinical trial web sites of manufacturers
(www.ctr.gsk.co.uk; www.astrazenecaclinicaltrials.com).
Searches are current to May 2009.
Data collection and analysis
Selection of studies
Following electronic literature searches, two review authors inde-
pendently selected articles on the basis of title and/or abstract for
full text scrutiny. The authors agreed a list of articles which were
retrieved, and they subsequently assessed each reference to deter-
mine whether it met the review eligibility criteria.
Data extraction and management
One author (TJL) extracted information from each study for the
following characteristics:
Design (description of randomisation, blinding, number of study
centres and location, number of study withdrawals).
Participants (N, mean age, age range of the study, gender ratio,
baseline lung function, % on maintenance ICS or ICS/LABA
combination & average daily dose of steroid (BDP equivalent),
entry criteria).
Intervention (type and dose of component ICS and LABA, dosing
schedule, inhaler device, study duration & run-in)
Outcomes (type of outcome analysis, outcomes analysed, numer-
ical data)
This information was double-checked by a second author (GF &
CJC).
Assessment of risk of bias in included studies
We assessed study quality according to whether studies met the
following pre-specified quality criteria (as yes, no or unclear,
Handbook 2005):
1. Allocation generation - was sequence generation
unpredictable?
2. Allocation concealment - were steps taken to prevent
foreknowledge of treatment group assignment?
3. Blinding - were the treatments known to the patients,
investigators and those assessing outcomes?
4. Withdrawal - were all participants who entered the study
accounted for, and was the analysis likely to be biased by the
handling of dropouts? This was considered in relation to the
outcomes of oral steroid requirement and hospital admission.
5. Selective reporting - was there evidence of unreported
outcome data in the trial report(s)?
6. Other bias - was the study free of other types of bias?
Additional information were sought on outcomes that were par-
tially reported from the study sponsors.
Dealing with missing data
Wecontacted study sponsors for additional datawhichwe required
for our primary outcomes of oral steroid-treated exacerbations,
and exacerbations leading to hospital admission.
Assessment of heterogeneity
We measured statistical variation between studies by the I square
statistic (Higgins 2003).Where this exceeded 20%we also applied
random effects modelling to assess whether assuming a distribu-
tion of related true effects (rather than a fixed true effect) altered
the pooled effect estimate.
Data synthesis
Data were combined with RevMan 5, using a a fixed effect odds
ratio for dichotomous variables, and a fixed effect mean difference
(calculated as either a weighted mean difference or a mean dif-
ference weighted by generic inverse variance) for continuous data
variables. For the primary outcome of exacerbations we calculated
NNT(benefit) for the different levels of risk as represented by con-
trol group event rates (www.nntonline.net), in order to express
the number of patients needed to be treated with intervention to
prevent one event from occurring.
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We generated a summary of findings table for the primary out-
comes in the review (exacerbations requiring oral steroids, exacer-
bations leading to hospital admission, and serious adverse events).
We generated the table with GRADEpro software.
Subgroup analysis and investigation of heterogeneity
We intended to subgroup data from adults, adolescents and chil-
dren in subgroups. Adult studieswere considered as thosewhich re-
cruited participants from 18 upwards. Adult and adolescent stud-
ies were considered as those which recruited participants from 12
upwards. We considered participants in studies where the upper
age limit was 12 years as children, and in studies where the upper
age limit was 18 years as children and adolescents. Despite this
categorisation we did not identify any studies performed in chil-
dren less than 12 years of age.
Subgroup analyses was performed based on the severity of asthma
as assessed according to international guidelines (GINA: con-
trolled, partly controlled, uncontrolled), and trials on patients us-
ing oral steroid treatmentwere considered separately.We restricted
subgroup analysis to our primary outcomes.
Sensitivity analysis
Sensitivity analysis was conducted on the risk of bias, where the
predefined quality criteria of randomisation, blinding and with-
drawal are met. We also considered the impact of dosing and in-
haler devices for both interventions. Funnel plots were inspected
to assess the presence of publication bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
From 747 references identified by literature searches up to May
2009, five studies (26 citations) met the entry criteria of the review.
Of these, four are full-text publications, and one is available as a
download from a manufacturer’s web site (SAM40048).
Details of the literature search and study assessment processes for
the 2009 literature search are provided in Figure 1. Four studies
(reported in five separate references) considered for this update
failed to meet the eligibility criteria (Adachi 2008; Ambrose 2007;
Bleecker 2007; Hampel 2007, see Characteristics of excluded
studies). A further six references from this search were identified as
additional publications from two included studies (COMPASS;
Busse 2008), and one excluded study (AHEAD).
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Figure 1. Literature flow diagram for the review.
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Included studies
Population
5537 adult and adolescent participants were recruited to the stud-
ies. The studies required participants to have a history of chronic
asthma, treated with maintenance inhaled corticosteroids at mod-
erate to high doses prior to study entry. In the five studies, par-
ticipants had to be stable for one month before the run-in pe-
riod. Once in the run-in phase, participants were further required
to demonstrate the need for frequent reliever inhaler use. On
the basis of these characteristics we adjudged the trial popula-
tions to be partly controlled, since the requirement for relief med-
ication was in addition to chronically applied inhaled steroids
(GINA). The severity of airway obstruction varied between the
trials, with the participants with the lowest percentage predicted
of FEV1 recruited to SAM40048 (65%), Busse 2008; EXCEL
and COMPASS recruiting participants with moderate airway ob-
struction (79%, 79%and 73% respectively), and participants with
milder obstruction represented in Aalbers 2004 (84%).
Interventions & comparisons
Converting the inhaled steroid load to BDP equivalent indicated
that the trials assessed high doses of inhaled steroids in both FP/
SAL and BUD/F groups, although FP/SAL was higher in BDP
equivalence terms than BUD/F (1000 versus 400-800 mcg/day).
All doses were given twice daily via different inhalers (Diskus and
Turbohaler for FP/SAL and BUD/F respectively). Two studies
were open label (Aalbers 2004; Busse 2008). In all studies the dose
of FP/SAL was 500/100 mcg/day, and that of BUD/F was 400-
800/12-24 mcg/day.
Concomitant use of reliever medication was permitted in all four
studies; terbutaline in COMPASS, salbutamol in Busse 2008 and
EXCEL, and terbutaline or salbutamol as preferred in Aalbers
2004. In SAM40048 the reliever medication was not reported.
Outcomes
Four trials measured exacerbations as oral steroid and hospitalisa-
tions (Aalbers 2004; Busse 2008; EXCEL; COMPASS), and also
gave numerical data for serious adverse events. All studies reported
lung function measurements. Data on admission to hospital were
made available to the review authors on request from GSK and
AZ for Aalbers 2004; COMPASS; EXCEL. We were informed
verbally that exacerbations were not collected in a way that was
suitable for us to use in our review in SAM40048.
Excluded studies
A total of 19 studies failed to meet the review eligibility criteria.
The reasons for their exclusion are listed in Characteristics of
excluded studies.
Risk of bias in included studies
See Figure 2 and Figure 3 for summaries of risk of bias. Addi-
tional details on items are provided in Characteristics of included
studies. Generally the studies were well designed although reliable
assessment of selective reporting could not be ascertained. Primary
outcome data were either reported in the studies or made available
to the authors on request.
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Figure 2. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as
percentages across all included studies.
Allocation
The four studies available as full-text articles reported computer-
generated randomisation sequences, with adequate concealment of
treatment group allocation.Demographic characteristics of all four
of the studies indicated that treatment groups were well balanced.
Details on SAM40048 were not adequately reported for us to
establish the appropriateness of the concealment of allocation.
Blinding
We used outcome data from an open label phase in two studies
(Aalbers 2004; Busse 2008). The remaining studies used a double-
dummy design to control for awareness of treatment group allo-
cation. Blinding of outcome assessment was not reported in the
studies.
Incomplete outcome data
Intention to treat analyses were used in all of the studies based on
the population randomised, but explicit description of follow-up
and handling of missing data were not provided.
Selective reporting
We needed to contact the study sponsors of Aalbers 2004;
COMPASS for data pertaining to our primary outcomes of exac-
erbations (AstraZeneca). The sponsors of EXCEL confirmed data
on the primary outcomes, and made available data for exacerba-
tions leading to ED visits and admission to hospital (see Published
notes).
Effects of interventions
See: Summary of findings for the main comparison
Combination fluticasone/salmeterol or budesonide/formoterol for
chronic asthma in adults
Using published data and unpublished data obtained through cor-
respondence with manufacturers, we included four of the five eli-
gible trials in the three co-primary outcomes representing 88% of
randomised participants.
FP/SAL 500/100 mcg/d versus BUD/F 400-800/12-24
mcg/d
The comparisons are presented such that a reduction in the mean
difference greater than 0, or an odds ratio of less than one repre-
sent a lowering for the FP/SAL group compared to the BUD/F
group (the associated confidence intervals and P value indicate the
statistical significance of this). In view of the absence of studies in
children, the evidence we have relates to adults.
Primary outcomes
Exacerbations & asthma related serious adverse events
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There was no significant difference in the risk of experiencing an
exacerbation requiring oral-steroid treatment (four studies, OR
0.89; 95% CI 0.74 to 1.07, N = 4515 Figure 4).
Figure 4. Forest plot of comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol,
outcome: 1.1 Participants experiencing exacerbations requiring oral steroid treatment.
Exacerbations resulting in admission to hospital were not signif-
icantly different between FP/SAL and BUD/F (four studies, OR
1.29; 95% CI 0.68 to 2.47, N = 4053 Figure 5).
Figure 5. Forest plot of comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol,
outcome: 1.2 Participants experiencing exacerbations requiring admission to hospital.
The risk of an asthma-related serious adverse event did not differ
significantly between treatments (three studies, OR 1.47; 95% CI
0.75 to 2.86, N = 4879 Figure 6).
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Figure 6. Forest plot of comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol,
outcome: 1.3 Asthma-related serious adverse event.
The Summary of Findings table conveys the results of these out-
comes as absolute effects and our assessment of the strength of the
evidence (Summary of findings for the main comparison).
Secondary outcomes
Exacerbations requiring ED visit/hospital admission
(composite)
There was no statistically significant difference in the odds of ED
visit/admission to hospital between the treatments (four studies,
OR 1.3; 95% CI 0.94 to 1.8, N = 4861, Analysis 1.4).
Diary card peak flow
There was no significant difference between treatments in mean
change in morning (five studies, 2.24 L/min, 95% CI -0.24 to
4.73, N = 5101) or evening peak flow (four studies, 0.25 L/min;
95% CI -0.80 to 1.30, N = 4299).
FEV1
There was no significant difference in the change from baseline
between treatments (three studies, 0 Litres; 95% CI -0.02 to 0.02,
N = 4845).
Symptoms & rescue medication use
There was no significant difference between treatments in the
mean change in symptom scores (three studies, -0.02; 95% CI -
0.6 to 0.03, N = 3464). There was also no significant difference
in change in rescue medication (three studies -0.06 puffs per day;
95% CI -0.13 to 0.02, N = 3469).
Withdrawals and tolerability
Study withdrawals were not significantly more frequent with ei-
ther treatment in terms of overall discontinuations (Analysis 1.13),
or when withdrawal due to adverse events or lack of efficacy were
considered Analysis 1.14; Analysis 1.15. Headache, upper respi-
ratory tract infection, dysphonia and throat irritation did not dif-
fer significantly between treatments (Analysis 1.17; Analysis 1.20;
Analysis 1.19; Analysis 1.22).
A summary of findings table has been incorporated to this version
of the review. This outlines our assessment of the overall quality
of the evidence based on the risk of bias assessments, availability
of data, imprecision of our analyses, and size and direction of the
results (Summary of findings for the main comparison). In view
of the absence of studies in children, the findings of the review are
directly relevant to adults with asthma.
D I S C U S S I O N
This review has collected data from five well-designed studies ran-
domising over 5000 patients. No studies recruited children under
the age of 12 years. The dose comparisons across the studies were
similar, except for SAM40048 where the dose of budesonide was
half of that in the other studies. Based on UK recommendations,
the BUD/F dose was the maximum licensed dosing for asthma in
the UK, and the FP/SAL dose is the medium dose recommended
in theUK for asthma (BNF 2007).We identified three co-primary
outcomes, two pertaining to different severities of asthma exacer-
bation (those requiring oral steroid treatment, and those leading
to hospitalisation), and one relating to asthma-related serious ad-
verse events. None of the results were statistically significant. Our
assessment of the quality of the evidence for these outcomes was
moderate. Findings from these three endpoints will be considered
first.
Requirement for a course of oral steroid treatment is a treatment-
driven rather than symptom-driven definition, but gives some in-
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dication as to whethermaintenance therapy reduces inflammation
sufficiently to prevent requirement for additional steroid. The ra-
tio of such events was close to 1 in the three studies, and the BUD/
F event rate was similar between the trials (Aalbers 2004: 15%;
Busse 2008: 9%; EXCEL: 11%; COMPASS: 10%). The lack of
a statistically significant difference may reflect the effectiveness of
combination therapy in reducing exacerbations when added to
monotherapy ICS (Greenstone 2005).
The risk of hospitalisation did not differ significantly between
therapies, although the confidence interval was wide and further
evidence is necessary before a conclusion of no difference could
be drawn definitively. The morbidity associated with hospital ad-
mission is considerable, and may indicate severe uncontrolled dis-
ease as well as predict future hospitalisation and mortality (Suissa
2001). Superiority of FP over BUD in dose ratio comparisons of 1:
1 and 1:2 has been demonstrated for lung function endpoints, but
not exacerbation rate data (Adams 2007). Our composite analy-
sis of ED visit/hospitalisation did not show a significant differ-
ence between the treatments in contrast to a previous meta-anal-
ysis (Edwards 2007). The data for that analysis were in part based
upon hospitalisation data from EXCEL and not additional ED
visits from that study. Given that the data we obtained from GSK
suggested parity between these event rates, we consider our data
to represent a more complete assessment of the evidence available.
Based on evidence of harm, the use of LABAs as monotherapy is
not recommended with serious adverse event data from previous
studies implicating the bronchodilatory effects of LABAs as a pos-
sible mask for under-treated deterioration in underlying airway
inflammation (Walters 2007; Cates 2008a; Cates 2008b). Serious
adverse events did not occur with sufficient frequency in the stud-
ies to give precision to the results of our meta-analysis. The relative
effects of either treatment in terms of serious harms remain to be
fully elucidated. Based on evidence drawn fromother comparisons
involving adding LABA to ICS preparations, these therapies are
well-tolerated (Greenstone 2005; Ni Chroinin 2005).
Neither lung function parameters, symptom scores nor rescue
medication use identified statistically significant differences be-
tween treatments. Adverse event data indicated that the drugs were
equally well-tolerated.
There are several limitations of the review. We limited our analyses
to parallel studies on the assumption that optimum washout in
steroid trials is uncertain, and that our primary outcome of exac-
erbations was best measured in long-term studies with a between-
patient design.We have assumed that requirement for oral steroids
and admission to hospital are independent, although it is reason-
able to expect that poor asthma control associated with lack of
adherence tomaintenance inhaled steroids is likely to predict both
(Williams 2004). Assessment of patient severity was confined to
GINAdefined control status, and this may not be sensitive enough
to discern between severities of asthma. The major limitation of
the studies themselves is the absence of data in children under the
age of 12 years.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The confidence intervals for our estimates in our primary out-
comes include no statistically significant difference. However, the
width of the confidence intervals for these endpoints also include
possibly meaningful differences between the treatments in either
direction and as such more evidence would help to improve their
precision. Serious adverse events were too infrequent to generate
findings which could be easily interpreted. Our analyses could not
detect significant differences between these drugs in terms of lung
function and symptoms. These observations pertain to adults and
adolescents whose asthma is not adequately controlled with high
doses of inhaled steroids.
Implications for research
The findings of our review would be strengthened bymore data on
exacerbations from further trials, in particular trials that include
visits to emergency departments and hospitalisation. Evidence is
required to establish the ratio of serious adverse events between
these two drugs. Evidence for the effects of these drugs in children
is also required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aalbers 2004
Methods Randomised, parallel group trial. Open label design with adjustable dosing criteria
93 centres in Denmark, Finland, Germany, Norway, Sweden, Netherlands
Description of withdrawals:
Stated.
Participants N SCREENED: Not reported (1044 enrolled in run-in period)
N RANDOMISED: 658: FPS fixed dose: 224; BDF fixed dose: 215; BDF adjustable
maintenance dose: 219 (not included in this review)
N COMPLETED: 383
M= 205
F= 234
MEAN AGE: 46
BASELINE CHARACTERISTICS:
FEV1% predicted: 84; PEF L/min: 468; % combination LABA/ICS treatment at entry:
45; asthma duration: 12; Average ICS dose (BDP equivalent): 735
GINA status: mild persistent
INCLUSION CRITERIA:
>12 years;minimum6months asthmaduration (ATSdefinition); FEV1predicted >50%;
ICS use >3 months; stable dose +/- LABA;
Post-run-in entry criteria: symptom score >1 on at least 4 of last 7 days of run-in period;
mean PEF of 50-85% predicted; use of PEF meter to record DC data
EXCLUSION CRITERIA:
Respiratory infection <4 weeks prior to study entry; smoking history >10 pack years; use
of systemic steroids within 4 weeks of study entry; significant co-morbidities
Interventions 1. Combination fluticasone and salmeterol 250/50 mcg bid (double-blind phase); 250/
50 bid fixed (open label phase). BDP equivalent 1000 mcg
2. Combination budesonide and formoterol 400/12mcg bid (double-blind phase); 400/
12 bid fixed (open label phase). BDP equivalent 800 mcg
3. Combination budesonide and formoterol 320/9 mcg bid (double-blind phase); 320/9
bid or 160/4.5 bid plus temporary increase if needed (open label period). BDP equivalent
800 mcg
DELIVERY DEVICE:
BUD/F: Turbuhaler; FP/SAL: Diskus
TREATMENT PERIOD:
Double-blind fixed dose period: 4 weeks; open label period: 24 weeks
RUN-IN: 10-14 days on ICS only
RESCUE: Terbutaline or salbutamol as preferred
Outcomes Primary outcome: Well controlled asthma week
Secondary outcomes:
Am PEF; pm PEF; FEV1; rescue medication use; symptoms; exacerbations (requiring
OCS treatment on >3 days; hospitalisation or ER treatment)
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Aalbers 2004 (Continued)
Notes DOSE ADJUSTMENT CRITERIA: Step down to one inhalation bid if symptoms
controlled for last week of double-blind period; increase to up to four inhalations bid
(for 7-14 days) of symptomatic over last week of double-blind period
Study sponsors: AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’The randomisation schedule was gener-
ated using a computer programme by a
statistician (...) Patients were consecutively
allocated to the lowest available patient
number and were randomised strictly se-
quentially in blocks.’
Allocation concealment? Yes Third party not involved with primary
study.
Blinding?
OCS treated exacerbations & hospitalisa-
tion
Yes Open label study design not a threat to pri-
mary outcomes in this review
Incomplete outcome data addressed?
OCS treated exacerbations
Unclear ITT analysis described; no explicit details
on how withdrawals were handled
Incomplete outcome data addressed?
Hospital admission
Unclear ITT analysis described; no explicit details
on how withdrawals were handled
Free of selective reporting? Unclear Unable to ascertain this reliably
Free of other bias? Yes
Busse 2008
Methods Randomised, parallel group open label design with adjustable dosing criteria (from
month 2 onwards). Participants randomised 2:1 to receive fixed dose BUD/F or FP/
SAL. Subsequently BUD/F treated participants were re-randomised to continue with
fixed dose regimen or adjustable maintenance dosing
145 centres in USA
Description of withdrawals: stated
Participants N SCREENED: 2080
N RANDOMISED: 1225
N COMPLETED: 1052
M= 490
F= 735
MEAN AGE: 39
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Busse 2008 (Continued)
BASELINE CHARACTERISTICS: FEV1 79% predicted
INCLUSION CRITERIA: >12 years; ATS defined asthma for 6 months; stable condi-
tion; pre-bronchodilator FEV1 >/=50% predicted; maintained on a daily medium-dose
ICS or ICS/LABA combination for 12 weeks or longer before screening
EXCLUSION CRITERIA: Systemic corticosteroid use within 30 days; 20 pack-year
or longer smoking history; significant disease, respiratory tract infection, or illness that
might interfere with lung function/study participation
Interventions 1. Combination fluticasone and salmeterol 250/50mcg BID
2. Combination budesonide and formoterol 400/12mcg BID
DELIVERY DEVICE: BUD/F: MDI; FP/SAL: DPI
TREATMENT PERIOD: 7 months
RUN-IN: 10-14 days
RESCUE: prn SABA
Outcomes Primary outcome: Time to first exacerbation
Secondary outcomes: Exacerbations requiring OCS; hospitalisation; ED visits; FEV1;
am PEF; symptoms; rescue medication use; adverse events; withdrawals
Notes Study sponsors: AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation se-
quence.
Allocation concealment? Yes Third party not involved with primary
study
Blinding?
OCS treated exacerbations & hospitalisa-
tion
Yes Open label study design not a threat to pri-
mary outcomes in this review
Incomplete outcome data addressed?
OCS treated exacerbations
Unclear Intention to treat population described as:
’Efficacy analyses included randomized pa-
tients who received 1 or more doses of ran-
domized studymedication and contributed
data sufficient to calculate 1 or more pri-
mary or secondary efficacy end points.’
Incomplete outcome data addressed?
Hospital admission
Unclear Intention to treat population described as:
’Efficacy analyses included randomized pa-
tients who received 1 or more doses of ran-
domized studymedication and contributed
data sufficient to calculate 1 or more pri-
mary or secondary efficacy end points.’
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Busse 2008 (Continued)
Free of selective reporting? Unclear Unable to ascertain this reliably.
Free of other bias? Yes
COMPASS
Methods Randomised, parallel group trial. Double-blind, treble-dummy design
235 centres in 16 countries.
Description of withdrawals: Stated
Participants N SCREENED: Not reported (4399 enrolled)
NRANDOMISED: 2228 (two treatment groups: FPS: 1123; BDF: 1105; one treatment
group not considered by this review: BDF (plus BDF as needed): 1107).
N COMPLETED: 2120
M= 932
F= 1296
MEAN AGE: 38 (N 12-17 years: 424; >18 years: 1696)
BASELINE CHARACTERISTICS:
FEV1 predicted: 73%; mean ICS consumption at baseline: 747mcg/d;
INCLUSION CRITERIA:
>12 years; ATS defined asthma for >6 months; use of ICS >3 months (500mcg/d FP
or equivalent); >50% predicted FEV1; >1 exacerbation in previous 12 months; use of
reliever medication >5 days of previous 7 during run-in.
EXCLUSION CRITERIA:
>puffs/d rescue medication on any day of run-in; asthma exacerbation during run-in;
use of systemic corticosteroids/respiratory infection affecting asthma control within 30
days of study entry
Interventions 1. Combination fluticasone and salmeterol 250/50 mcg bid. BDP equivalent 1000 mcg
2. Combination budesonide and formoterol 400/12 mcg bid. BDP equivalent 800 mcg
3. Combination budesonide/formoterol 200/6mcg bid (plus additional puffs as required)
DELIVERY DEVICE: FPS: MDI; BDF: DPI
TREATMENT PERIOD: 24 weeks
RUN-IN: 2 weeks - regular ICS therapy plus terbutaline prn
RESCUE: Terbutaline
Outcomes Primary outcome: Time to first severe exacerbation
Secondary outcomes: Exacerbations; lung function (FEV1; diary card PEF); rescue med-
ication use; symptom scores”
Notes Dose adjustment criteria: Symptoms and rescue medication use determined whether
treatment should be increased. If absence of symptoms & rescue medication use (>/= 6
puffs/d or nocturnal symptoms) then maintenance treatment was stepped down
Study sponsors: AstraZeneca
Risk of bias
Item Authors’ judgement Description
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COMPASS (Continued)
Adequate sequence generation? Yes ’The randomisation schedule was com-
puter-generated at AstraZeneca Research
and Development, Charnwood, UK.
Within each centre, patients were ran-
domised strictly sequentially as they be-
came eligible.’
Allocation concealment? Yes Third party not involved in the primary
study.
’Individual treatment codes and code en-
velopes
(indicating the treatment allocation for
each
randomised patient) were provided, but
code envelopes were to be opened only in
case of medical emergencies.’
Blinding?
OCS treated exacerbations & hospitalisa-
tion
Yes Participants and investigators blinded to
treatment group assignment. Blinding
achieved with treble-dummy design; par-
ticipants given three devices (two matched
for maintenance administration of drug
and one as reliever)
Incomplete outcome data addressed?
OCS treated exacerbations
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Incomplete outcome data addressed?
Hospital admission
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Free of selective reporting? Yes Unable to ascertain this reliably.
Free of other bias? Yes
EXCEL
Methods Randomised, parallel group trial. Double-blind, double-dummy design
178 centres in 18 countries.
Description of withdrawals:
Stated
Participants N SCREENED: 1769
N RANDOMISED: 1397 (FPS: 694; BDF: 697)
N COMPLETED: 1258
M= 595
F= 796
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EXCEL (Continued)
MEAN AGE: 46
BASELINE CHARACTERISTICS:
FEV1 predicted: 79%; 353 L/min am PEF
INCLUSION CRITERIA:
>18 years; clinical history of asthma (>6 months); 1000-2000mcg/d BDP equivalent;
reversibility of 12%& 200mL or more post SABA; 2 or more episodes of asthma during
day/night on 4 of last 7 days of run-in.
EXCLUSION:
Upper/lower RTI; hospitalisation with asthma in 4 weeks prior to baseline visit; oral
steroids within 4 weeks/depot steroids within 12 weeks of baseline visit; FEV1 <50%
predicted; smoking history of >10 pack years
Interventions 1. Combination fluticasone and salmeterol 250/50 mcg bid (+ placebo turbuhaler). BDP
equivalent 1000 mcg
2. Combination budesonide and formoterol 400/12 mcg bid (+ placebo Diskus). BDP
equivalent 800 mcg
DELIVERY: FPS: Diskus; BDF: Turbuhaler
TREATMENT PERIOD: 24 weeks
RUN-IN:
ICS + salbutamol prn (2 weeks)
RESCUE: Salbutamol
Outcomes Primary outcome: rate of exacerbations
Secondary outcomes:
Exacerbations (use of oral steroids; hospitalisations); asthma symptoms; rescue medica-
tion use; am PEF; pm PEF; FEV1; withdrawals; adverse events
Notes Study sponsors: GSK
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Patients were assigned to study treatment
in accordance with the randomisation
schedule from the Interactive Voice
Recognition System, which was part of the
GSK
System for the Central Allocation of Med-
ication.’
Allocation concealment? Yes Third party not involved with primary
study
Blinding?
OCS treated exacerbations & hospitalisa-
tion
Yes All treatment packs contained bothDiskus/
Accuhaler and Turbuhaler devices (ei-
ther active Diskus/Accuhaler+placebo Tur-
buhaler, or active Turbuhaler+placebo
Diskus/Accuhaler) and looked identical
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EXCEL (Continued)
Incomplete outcome data addressed?
OCS treated exacerbations
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Incomplete outcome data addressed?
Hospital admission
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Free of selective reporting? Unclear Unable to ascertain this reliably
Free of other bias? Yes
SAM40048
Methods Randomised, parallel group trial. Double-blind, double dummy design
27 centres in Germany.
Description of withdrawals:
Stated
Participants N SCREENED: Not reported
N RANDOMISED: 248 (ITT population: 241)
N COMPLETED: 235
M= 102 (based on ITT)
F= 139 (based on ITT)
MEAN AGE: 48
BASELINE CHARACTERISTICS: FEV1 predicted: 65%; am PEF 310 L/min
INCLUSION CRITERIA:
‘Moderate’ asthma; >18 years; FEV1 50-80% predicted; >15% reversibility; ICS dose
1000 mcg/d (BDP equivalent); symptomatic (symptom score of 1 on 7 days of the run-
in period).
EXCLUSION CRITERIA: Exacerbations/emergency visits during 4-week pre-study
period; smoking (>20 cigarettes/d)
Interventions 1. Combination fluticasone and salmeterol 250/50 mcg bid + placebo Turbohaler. BDP
equivalent 1000 mcg
2. Combination budesonide and formoterol 200/6mcg bid + placebo Diskus inhaler.
BDP equivalent 400 mcg
DELIVERY DEVICE: FPS: Diskus; BDF: Turbohaler
TREATMENT PERIOD: 12 weeks
RUN-IN: 2 weeks (treatment not clear)
RESCUE: Not reported
Outcomes Primary outcome: FEV1 predicted
Secondary outcomes: Morning PEF; evening PEF; daytime and evening asthma symp-
toms; symptom-free days; rescue medication-free days; safety
Notes Study sponsors: GSK
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SAM40048 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available.
Allocation concealment? Unclear Not reported
Blinding?
OCS treated exacerbations & hospitalisa-
tion
Yes Participants and investigators blinded to
treatment group allocation with double-
dummy design
Incomplete outcome data addressed?
OCS treated exacerbations
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Incomplete outcome data addressed?
Hospital admission
Unclear ITT analysis described. Explicit details of
how withdrawals handled were not de-
scribed
Free of selective reporting? Unclear Unable to ascertain this reliably
Free of other bias? Yes
ATS: American Thoracic Society; BDF: budesonide/formoterol; BDP: Beclomethasone; BID: twice daily; DPI: Dry powder inhaler;
FEV1: Forced expiratory volume in 1 second; FPS: Fluticasone/salmeterol combination; ICS: inhaled corticosteroid; MDI: metered
dose inhaler; PEF: peak expiratory flow; RTI: Respiratory tract infection; SABA: Short-acting beta-agonist.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adachi 2008 Study compared combination FP/SAL with FP and theophylline.
AHEAD Study comparing FP/SAL with BUD/F as an adjustable dosing strategy
ALLIANCE Combinations assessed not relevant to this review.
Ambrose 2007 Study compared different doses of BUD/F. No comparison with FP/SAL
Bleecker 2007 Study randomised participants to FP/SAL or SAL. No comparison with BUD/F
Brambilla 2003 Separate inhalers: Formoterol versus Salmeterol as add on to ICS
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(Continued)
CONCEPT Assessment of combination FP/SAL against BUD/F given as an adjustable dosing strategy
Creemers 2002 Study summarised data from two studies comparing BDF with ICS alone
EDICT Combination FPS versus BUD/F given via separate inhalers.
Hampel 2007 Report of two crossover studies: ineligible design.
Jenkins 2000 Study assessed FPS with ICS alone.
Kaik 2002 Separate F and BUD preparations versus combination FPS.
Lee 2003 Crossover design.
Lotväll 2002 Summary of two crossover studies.
Palmqvist 2001 Crossover design.
SAM40042 Crossover design.
SAM40047 Crossover design.
SAM40062 Crossover design.
Vogelmeier 2005 Comparison of FP/SAL with BUD/F as maintenance and relief.
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D A T A A N D A N A L Y S E S
Comparison 1. Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants experiencing
exacerbations requiring oral
steroid treatment
4 4949 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.74, 1.07]
2 Participants experiencing
exacerbations requiring
admission to hospital
4 4879 Odds Ratio (M-H, Fixed, 95% CI) 1.29 [0.68, 2.47]
3 Asthma-related serious adverse
event
3 4054 Odds Ratio (M-H, Fixed, 95% CI) 1.47 [0.75, 2.86]
4 Participants experiencing
exacerbations requiring ED
visit/hospitalisation
4 4861 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.94, 1.80]
5 Change in FEV1 4 4845 L (Fixed, 95% CI) Not estimable
6 Change in FEV1 predicted (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Change in am PEF 5 5101 L/min (Fixed, 95% CI) 2.24 [-0.24, 4.73]
8 Change in pm PEF 4 4299 L/min (Fixed, 95% CI) 0.25 [-0.80, 1.30]
9 Change in daytime symptoms 3 3464 Symptoms (Fixed, 95% CI) -0.02 [-0.06, 0.03]
10 Change in symptom-free days 2 3027 Symptoms (Fixed, 95% CI) 1.25 [-1.18, 3.67]
11 Change in nocturnal
awakenings
1 Symptoms (Fixed, 95% CI) Totals not selected
12 Change in rescue medication
use
3 3469 Puffs/d (Fixed, 95% CI) -0.06 [-0.13, 0.02]
13 Withdrawals 5 5082 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.78, 1.20]
14 Withdrawals (adverse events) 5 5082 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.60, 1.46]
15 Withdrawals (lack of efficacy) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
16 Adverse events 2 1644 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.89, 1.31]
17 Headache 4 2916 Odds Ratio (M-H, Fixed, 95% CI) 1.08 [0.82, 1.43]
18 Candidiasis 2 1272 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.68, 4.00]
19 Dysphonia 3 2669 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.87, 2.43]
20 Upper respiratory tract
infection
2 1644 Odds Ratio (M-H, Fixed, 95% CI) 1.09 [0.81, 1.47]
21 Rhinitis 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
22 Throat irritation 2 1644 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.82, 2.35]
23 Cough 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
24 Tremor 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 1
Participants experiencing exacerbations requiring oral steroid treatment.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 1 Participants experiencing exacerbations requiring oral steroid treatment
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 30/219 33/215 12.2 % 0.88 [ 0.51, 1.49 ]
Busse 2008 37/404 37/422 13.9 % 1.05 [ 0.65, 1.69 ]
COMPASS 109/1199 108/1099 43.5 % 0.92 [ 0.69, 1.21 ]
EXCEL 63/694 79/697 30.4 % 0.78 [ 0.55, 1.11 ]
Total (95% CI) 2516 2433 100.0 % 0.89 [ 0.74, 1.07 ]
Total events: 239 (FP/SAL), 257 (BUD/F)
Heterogeneity: Chi2 = 1.04, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
0.1 0.2 0.5 1 2 5 10
Favours FP/SAL Favours BUD/F
Analysis 1.2. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 2
Participants experiencing exacerbations requiring admission to hospital.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 2 Participants experiencing exacerbations requiring admission to hospital
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 0/219 1/215 9.2 % 0.33 [ 0.01, 8.04 ]
Busse 2008 2/404 1/422 5.9 % 2.09 [ 0.19, 23.19 ]
COMPASS 15/1123 13/1105 78.8 % 1.14 [ 0.54, 2.40 ]
EXCEL 4/694 1/697 6.0 % 4.03 [ 0.45, 36.19 ]
Total (95% CI) 2440 2439 100.0 % 1.29 [ 0.68, 2.47 ]
Total events: 21 (FP/SAL), 16 (BUD/F)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
0.001 0.01 0.1 1 10 100 1000
Favours FP/SAL Favours BUD/F
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Analysis 1.3. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 3
Asthma-related serious adverse event.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 3 Asthma-related serious adverse event
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 0/224 1/215 10.6 % 0.32 [ 0.01, 7.86 ]
COMPASS 15/1119 12/1099 82.6 % 1.23 [ 0.57, 2.64 ]
EXCEL 6/697 1/700 6.8 % 6.07 [ 0.73, 50.55 ]
Total (95% CI) 2040 2014 100.0 % 1.47 [ 0.75, 2.86 ]
Total events: 21 (FP/SAL), 14 (BUD/F)
Heterogeneity: Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 1.12 (P = 0.26)
0.001 0.01 0.1 1 10 100 1000
Favours FP/SAL Favours BUD/F
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Analysis 1.4. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 4
Participants experiencing exacerbations requiring ED visit/hospitalisation.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 4 Participants experiencing exacerbations requiring ED visit/hospitalisation
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 7/219 3/215 4.6 % 2.33 [ 0.60, 9.14 ]
Busse 2008 2/404 4/422 6.1 % 0.52 [ 0.09, 2.85 ]
COMPASS 70/1123 50/1105 73.9 % 1.40 [ 0.97, 2.04 ]
EXCEL 8/686 10/687 15.4 % 0.80 [ 0.31, 2.04 ]
Total (95% CI) 2432 2429 100.0 % 1.30 [ 0.94, 1.80 ]
Total events: 87 (FP/SAL), 67 (BUD/F)
Heterogeneity: Chi2 = 3.02, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 1.57 (P = 0.12)
0.005 0.1 1 10 200
Favours FP/SAL Favours BUD/F
Analysis 1.5. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 5
Change in FEV1.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 5 Change in FEV1
Study or subgroup FP/SAL BUD/F L (SE) L Weight L
N N IV,Fixed,95% CI IV,Fixed,95% CI
Aalbers 2004 224 215 -0.06 (0.03) 12.9 % -0.06 [ -0.12, 0.00 ]
Busse 2008 391 396 0.02 (0.0204) 28.0 % 0.02 [ -0.02, 0.06 ]
COMPASS 1123 1105 0 (0.0158) 46.6 % 0.0 [ -0.03, 0.03 ]
EXCEL 694 697 0.02 (0.0306) 12.4 % 0.02 [ -0.04, 0.08 ]
Total (95% CI) 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Chi2 = 5.39, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours BUD/F Favours FP/SAL
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Analysis 1.6. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 6
Change in FEV1 predicted (%).
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 6 Change in FEV1 predicted (%)
Study or subgroup FP/SAL BUD/F Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
SAM40048 116 14 (16.4) 125 10.9 (13.3) 3.10 [ -0.69, 6.89 ]
-10 -5 0 5 10
Favours BUD/F Favours FP/SAL
Analysis 1.7. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 7
Change in am PEF.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 7 Change in am PEF
Study or subgroup FP/SAL BUD/F L/min (SE) L/min Weight L/min
N N IV,Fixed,95% CI IV,Fixed,95% CI
Aalbers 2004 224 215 0.9 (3.74) 11.5 % 0.90 [ -6.43, 8.23 ]
Busse 2008 397 405 4.34 (3.2602) 15.2 % 4.34 [ -2.05, 10.73 ]
COMPASS 1123 1105 2.5 (1.8878) 45.2 % 2.50 [ -1.20, 6.20 ]
EXCEL 694 697 0.4 (2.4745) 26.3 % 0.40 [ -4.45, 5.25 ]
SAM40048 116 125 14.04 (9.5714) 1.8 % 14.04 [ -4.72, 32.80 ]
Total (95% CI) 100.0 % 2.24 [ -0.24, 4.73 ]
Heterogeneity: Chi2 = 2.64, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours BUD/F Favours FP/SAL
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Analysis 1.8. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 8
Change in pm PEF.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 8 Change in pm PEF
Study or subgroup FP/SAL BUD/F L/min (SE) L/min Weight L/min
N N IV,Fixed,95% CI IV,Fixed,95% CI
Aalbers 2004 224 215 -1.1 (3.45) 2.4 % -1.10 [ -7.86, 5.66 ]
COMPASS 1123 1105 0.7 (1.8622) 8.2 % 0.70 [ -2.95, 4.35 ]
EXCEL 694 697 0.2 (0.5663) 89.1 % 0.20 [ -0.91, 1.31 ]
SAM40048 116 125 14.42 (9.9642) 0.3 % 14.42 [ -5.11, 33.95 ]
Total (95% CI) 100.0 % 0.25 [ -0.80, 1.30 ]
Heterogeneity: Chi2 = 2.24, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours BUD/F Favours FP/SAL
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Analysis 1.9. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome 9
Change in daytime symptoms.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 9 Change in daytime symptoms
Study or subgroup FP/SAL BUD/F Symptoms (SE) Symptoms Weight Symptoms
N N IV,Fixed,95% CI IV,Fixed,95% CI
Aalbers 2004 224 215 -0.05 (0.06) 14.1 % -0.05 [ -0.17, 0.07 ]
Busse 2008 395 402 0.02 (0.0357) 39.8 % 0.02 [ -0.05, 0.09 ]
COMPASS 1123 1105 -0.04 (0.0332) 46.1 % -0.04 [ -0.11, 0.03 ]
Total (95% CI) 100.0 % -0.02 [ -0.06, 0.03 ]
Heterogeneity: Chi2 = 1.86, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours FP/SAL Favours BUD/F
Analysis 1.10. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
10 Change in symptom-free days.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 10 Change in symptom-free days
Study or subgroup FP/SAL BUD/F Symptoms (SE) Symptoms Weight Symptoms
N N IV,Fixed,95% CI IV,Fixed,95% CI
Busse 2008 395 404 0.18 (2.4821) 24.9 % 0.18 [ -4.68, 5.04 ]
COMPASS 1123 1105 1.6 (1.4286) 75.1 % 1.60 [ -1.20, 4.40 ]
Total (95% CI) 100.0 % 1.25 [ -1.18, 3.67 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours BUD/F Favours FP/SAL
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Analysis 1.11. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
11 Change in nocturnal awakenings.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 11 Change in nocturnal awakenings
Study or subgroup FP/SAL BUD/F Symptoms (SE) Symptoms Symptoms
N N IV,Fixed,95% CI IV,Fixed,95% CI
COMPASS 1123 1105 -0.2 (0.8163) -0.20 [ -1.80, 1.40 ]
-4 -2 0 2 4
Favours FP/SAL Favours BUD/F
Analysis 1.12. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
12 Change in rescue medication use.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 12 Change in rescue medication use
Study or subgroup FP/SAL BUD/F Puffs/d (SE) Puffs/d Weight Puffs/d
N N IV,Fixed,95% CI IV,Fixed,95% CI
Aalbers 2004 224 215 -0.03 (0.11) 12.0 % -0.03 [ -0.25, 0.19 ]
Busse 2008 396 406 0.07 (0.0867) 19.3 % 0.07 [ -0.10, 0.24 ]
COMPASS 1123 1105 -0.1 (0.0459) 68.8 % -0.10 [ -0.19, -0.01 ]
Total (95% CI) 100.0 % -0.06 [ -0.13, 0.02 ]
Heterogeneity: Chi2 = 3.08, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours FP/SAL Favours BUD/F
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Analysis 1.13. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
13 Withdrawals.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 13 Withdrawals
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 25/224 31/215 16.1 % 0.75 [ 0.42, 1.31 ]
Busse 2008 37/391 37/389 19.3 % 0.99 [ 0.62, 1.61 ]
COMPASS 45/1119 53/1099 29.5 % 0.83 [ 0.55, 1.24 ]
EXCEL 71/697 62/700 31.9 % 1.17 [ 0.82, 1.67 ]
SAM40048 7/121 6/127 3.2 % 1.24 [ 0.40, 3.80 ]
Total (95% CI) 2552 2530 100.0 % 0.97 [ 0.78, 1.20 ]
Total events: 185 (FP/SAL), 189 (BUD/F)
Heterogeneity: Chi2 = 2.65, df = 4 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
0.1 0.2 0.5 1 2 5 10
Favours FP/SAL Favours BUD/F
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Analysis 1.14. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
14 Withdrawals (adverse events).
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 14 Withdrawals (adverse events)
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 9/224 10/215 24.2 % 0.86 [ 0.34, 2.15 ]
Busse 2008 5/391 5/389 12.2 % 0.99 [ 0.29, 3.46 ]
COMPASS 10/1119 13/1099 32.2 % 0.75 [ 0.33, 1.73 ]
EXCEL 13/697 10/700 24.2 % 1.31 [ 0.57, 3.01 ]
SAM40048 2/121 3/127 7.1 % 0.69 [ 0.11, 4.23 ]
Total (95% CI) 2552 2530 100.0 % 0.94 [ 0.60, 1.46 ]
Total events: 39 (FP/SAL), 41 (BUD/F)
Heterogeneity: Chi2 = 1.04, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
0.1 0.2 0.5 1 2 5 10
Favours FP/SAL Favours BUD/F
Analysis 1.15. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
15 Withdrawals (lack of efficacy).
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 15 Withdrawals (lack of efficacy)
Study or subgroup FP/SAL BUD/F Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 5/697 2/700 2.52 [ 0.49, 13.04 ]
0.1 0.2 0.5 1 2 5 10
Favours FP/SAL Favours BUD/F
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Analysis 1.16. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
16 Adverse events.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 16 Adverse events
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 384/697 377/700 87.4 % 1.05 [ 0.85, 1.30 ]
SAM40048 44/121 39/126 12.6 % 1.27 [ 0.75, 2.16 ]
Total (95% CI) 818 826 100.0 % 1.08 [ 0.89, 1.31 ]
Total events: 428 (FP/SAL), 416 (BUD/F)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.44)
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Analysis 1.17. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
17 Headache.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 17 Headache
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 9/224 4/215 4.2 % 2.21 [ 0.67, 7.28 ]
Busse 2008 3/406 6/427 6.2 % 0.52 [ 0.13, 2.10 ]
EXCEL 101/697 95/700 86.5 % 1.08 [ 0.80, 1.46 ]
SAM40048 2/121 3/126 3.1 % 0.69 [ 0.11, 4.20 ]
Total (95% CI) 1448 1468 100.0 % 1.08 [ 0.82, 1.43 ]
Total events: 115 (FP/SAL), 108 (BUD/F)
Heterogeneity: Chi2 = 2.66, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 1.18. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
18 Candidiasis.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 18 Candidiasis
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 7/224 4/215 50.7 % 1.70 [ 0.49, 5.90 ]
Busse 2008 6/406 4/427 49.3 % 1.59 [ 0.44, 5.66 ]
Total (95% CI) 630 642 100.0 % 1.64 [ 0.68, 4.00 ]
Total events: 13 (FP/SAL), 8 (BUD/F)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 1.19. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
19 Dysphonia.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 19 Dysphonia
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aalbers 2004 16/224 2/215 7.8 % 8.19 [ 1.86, 36.07 ]
Busse 2008 3/406 7/427 27.9 % 0.45 [ 0.11, 1.74 ]
EXCEL 17/697 16/700 64.2 % 1.07 [ 0.54, 2.13 ]
Total (95% CI) 1327 1342 100.0 % 1.45 [ 0.87, 2.43 ]
Total events: 36 (FP/SAL), 25 (BUD/F)
Heterogeneity: Chi2 = 8.88, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 1.20. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
20 Upper respiratory tract infection.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 20 Upper respiratory tract infection
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 101/697 94/700 96.5 % 1.09 [ 0.81, 1.48 ]
SAM40048 3/121 3/126 3.5 % 1.04 [ 0.21, 5.27 ]
Total (95% CI) 818 826 100.0 % 1.09 [ 0.81, 1.47 ]
Total events: 104 (FP/SAL), 97 (BUD/F)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
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Analysis 1.21. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
21 Rhinitis.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 21 Rhinitis
Study or subgroup FP/SAL BUD/F Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 45/697 34/700 1.35 [ 0.85, 2.14 ]
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Analysis 1.22. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
22 Throat irritation.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 22 Throat irritation
Study or subgroup FP/SAL BUD/F Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 32/697 23/700 91.9 % 1.42 [ 0.82, 2.45 ]
SAM40048 2/121 2/126 8.1 % 1.04 [ 0.14, 7.52 ]
Total (95% CI) 818 826 100.0 % 1.39 [ 0.82, 2.35 ]
Total events: 34 (FP/SAL), 25 (BUD/F)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 1.23. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
23 Cough.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 23 Cough
Study or subgroup FP/SAL BUD/F Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EXCEL 25/697 22/700 1.15 [ 0.64, 2.05 ]
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Analysis 1.24. Comparison 1 Combination fluticasone/salmeterol versus budesonide/formoterol, Outcome
24 Tremor.
Review: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Comparison: 1 Combination fluticasone/salmeterol versus budesonide/formoterol
Outcome: 24 Tremor
Study or subgroup FP/SAL BUD/F Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Busse 2008 1/406 8/427 0.13 [ 0.02, 1.04 ]
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WH A T ’ S N E W
Last assessed as up-to-date: 20 January 2010.
Date Event Description
8 May 2009 New search has been performed Literature search re-run: no new studies identified. Risk of bias table completed
and Summary of Findings table added
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 3, 2008
Date Event Description
19 June 2008 Amended Data from Aalbers 2004 added to the primary endpoint (OCS-treated exacerbations)
13 May 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
TJL devised the protocol with editorial support from CJC; Assessed studies, extracted data, contacted trialists and study sponsors for
additional outcome data; analysis and write-up
GF developed the protocol; wrote up study characteristics, extracted data and assisted with development of discussion section.
LC developed discussion section.
CJC: helped with data extraction and checking, interpretation and guidance on conceptual issues.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Added items to the risk of bias tool (allocation generation, selective reporting bias & other bias domains).
N O T E S
A previous version of this review was withdrawn prior to publication following the identification of incomplete data by GSK for the
outcome ED visit/admission to hospital. The data included in the original version of the review indicated a significant increase in the
odds of ED visit/hospitalisation with FP/SAL. However, this reflected data that were drawn from those participants who were admitted
to hospital only. The pooled outcome data did not an accurately represent the composite outcome of presentation at ED or hospital
admission (EXCEL). We have now included data made available to us by GSK which are an accurate record of ED visit or admission
to hospital.
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Medical Subject Headings (MeSH)
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[∗administration & dosage]; Asthma [∗drug therapy]; Budesonide [administration & dosage]; Drug Combinations; Ethanolamines
[administration & dosage]; Randomized Controlled Trials as Topic
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